1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Karen Carty: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer IMM-101, Pembrolizumab, Gemcitabine - Neoplasms Pancreatic | Phase 2 | Withdrawn | Karen Carty | 2024-06-17 | 2025-07-11 |
Gemcitabine (1) · IMM-101 (1) · pembrolizumab (1)
United Kingdom (1)
David Chang (1) · Jeff Evans (1)